The need for treatment responsive translational biomarkers in alcoholism research

Current Topics in Behavioral Neurosciences

Volumn 28, Issue , 2016, Pages 151-171

  Heilig, Markus ^a   Sommer, Wolfgang H ^b   Spanagel, Rainer ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alcohol endophenotype; Biomarker genetics glutamate; CRF naltrexone dopamine; Research domain criteria

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DOPAMINE; GLUTAMIC ACID; NALMEFENE; NALTREXONE; RACLOPRIDE; BIOLOGICAL MARKER;

ALCOHOLISM; ENDOPHENOTYPE; ENZYME ACTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADDICTION; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; METABOLISM; TRANSLATIONAL RESEARCH;

ALCOHOLISM; ANIMALS; BEHAVIOR, ADDICTIVE; BIOMARKERS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; ENDOPHENOTYPES; GLUTAMIC ACID; HUMANS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84988672471     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2015_5006     Document Type: Chapter

References (103)

1. Altshuler HL, Phillips PE, Feinhandler DA (1980) Alteration of ethanol self-administration by naltrexone. Life Sci 26: 679-688
2. American Psychiatric Association (2000) Diagnostic criteria from DSM-IV-TR. American Psychiatric Association, Washington, D.C.
3. Anderson P, Chisholm D, Fuhr DC (2009) Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet 373: 2234-2246
4. Bak LK, Schousboe A, Waagepetersen HS (2006) The glutamate/GABA-glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem 98: 641-653
5. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M (2007) Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry 64: 369-376
6. Bilbao A, Robinson JE, Heilig M, Malanga CJ, Spanagel R, Sommer WH, Thorsell A (2014) A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. Biol Psychiatry
7. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008) A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. AJ Psychiatry 165: 617-620
8. Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, Diksic M, Tremblay RE, Dagher A (2003) Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49: 226-231
9. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95: 9608-9613
10. Brand I, Fliegel S, Spanagel R, Noori HR (2013) Global ethanol-induced enhancements of monoaminergic neurotransmission: a meta-analysis study. Alcohol Clin Exp Res 37: 2048-2057
11. Broos N, Schmaal L, Wiskerke J, Kostelijk L, Lam T, Stoop N, Weierink L, Ham J, de Geus EJ, Schoffelmeer AN, van den Brink W, Veltman DJ, de Vries TJ, Pattij T, Goudriaan AE (2012) The relationship between impulsive choice and impulsive action: a cross-species translational study. PLoS ONE 7: e36781
12. Camchong J, Stenger VA, Fein G (2013) Resting-state synchrony in short-term versus long-term abstinent alcoholics. Alcohol Clin Exp Res 37: 794-803
13. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE (2010) Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. AJ Psychiatry 167: 509-527
14. Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ (2012) Association of mu-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 17: 505-512
15. Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, Fox GB, Day M (2011) Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharmacol Exp Ther 336: 709-715
16. Cippitelli A, Karlsson C, Shaw JL, Thorsell A, Gehlert DR, Heilig M (2010) Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology 211: 367-375
17. Compton WM, Dawson DA, Goldstein RB, Grant BF (2013) Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend 132(1): 387-390
18. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang SP, Emison E, Delmonte T, D’Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417-425
19. Culverhouse R, Bucholz KK, Crowe RR, Hesselbrock V, Nurnberger JI Jr, Porjesz B, Schuckit MA, Reich T, Bierut LJ (2005) Long-term stability of alcohol and other substance dependence diagnoses and habitual smoking: an evaluation after 5 years. Arch Gen Psychiatry 62: 753-760
20. Cuthbert BN (2014) Translating intermediate phenotypes to psychopathology: the NIMH research domain criteria. Psychophysiology 51: 1205-1206
21. Dahchour A, De Witte P (1999) Effect of repeated ethanol withdrawal on glutamate microdialysate in the hippocampus. Alcohol Clin Exp Res 23: 1698-1703
22. Dahchour A, De Witte P, Bolo N, Nedelec JF, Muzet M, Durbin P, Macher JP (1998) Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res 82: 107-114
23. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP (1993) Striatal binding of the PET ligand 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13: 350-356
24. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85: 5274-5278
25. Dudek M, Abo-Ramadan U, Hermann D, Brown M, Canals S, Sommer WH, Hyytia P (2014) Brain activation induced by voluntary alcohol and saccharin drinking in rats assessed with manganese-enhanced magnetic resonance imaging. Addiction biology
26. Edwards G, Gross MM (1976) Alcohol dependence: provisional description of a clinical syndrome. Br Med J 1: 1058-1061
27. Egli M (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 10: 309-319
28. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A, Eckelman WC, Carson RE (1997) Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J Cereb Blood Flow Metab 17: 932-942
29. Fliegel S, Brand I, Spanagel R, Noori HR (2013) Ethanol-induced alterations of amino acids measured by in vivo microdialysis in rats: a meta-analysis. Silico Pharmacology 1: 7
30. Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV (2014) Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction
31. Gass JT, Trantham-Davidson H, Kassab AS, Glen WB Jr, Olive MF, Chandler LJ (2014) Enhancement of extinction learning attenuates ethanol-seeking behavior and alters plasticity in the prefrontal cortex. J Neurosci 34: 7562-7574
32. Gilman JM, Ramchandani VA, Crouss T, Hommer DW (2012) Subjective and neural responses to intravenous alcohol in young adults with light and heavy drinking patterns. Neuropsychopharmacology 37: 467-477
33. Gilman JM, Ramchandani VA, Davis MB, Bjork JM, Hommer DW (2008) Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J Neurosci 28: 4583-4591
34. Ginovart N (2005) Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism. Molecular imaging and biology: MIB: the official publication of the Academy of Molecular Imaging 7: 45-52
35. Gladstone DJ, Black SE, Hakim AM, Heart, Stroke Foundation of Ontario Centre of Excellence in Stroke R (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33: 2123-2136
36. Glockner-Rist A, Lemenager T, Mann K, Group PSR (2013) Reward and relief craving tendencies in patients with alcohol use disorders: results from the PREDICT study. Addict Behav 38: 1532-1540
37. Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci 18: 10663-10671
38. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. AJ Psychiatry 160: 636-645
39. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K (2004) Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 61: 807-816
40. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther 111: 855-876
41. Heilig M, Egli M, Crabbe JC, Becker HC (2010) Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol 15: 169-184
42. Heilig M, Goldman D, Berrettini W, O’Brien CP (2011) Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 12: 670-684
43. Heilig M, Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30: 399-406
44. Hermann D, Weber-Fahr W, Sartorius A, Hoerst M, Frischknecht U, Tunc-Skarka N, Perreau-Lenz S, Hansson AC, Krumm B, Kiefer F, Spanagel R, Mann K, Ende G, Sommer WH (2012) Translational magnetic resonance spectroscopy reveals excessive central glutamate levels during alcohol withdrawal in humans and rats. Biol Psychiatry 71: 1015-1021
45. Hester RK, Miller WR (1995) Handbook of alcoholism treatment approaches: effective alternatives. Allyn & Bacon, Boston
46. Holmes A, Spanagel R, Krystal JH (2013) Glutamatergic targets for new alcohol medications. Psychopharmacology 229: 539-554
47. Hudson J, Khazragui HF (2013) Into the valley of death: research to innovation. Drug Discovery Today 18: 610-613
48. Hurd R, Sailasuta N, Srinivasan R, Vigneron DB, Pelletier D, Nelson SJ (2004) Measurement of brain glutamate using TE-averaged PRESS at 3T. Magn Reson Med 51: 435-440
49. Hyman SE (2012) Revolution stalled. Sci Trans Med 4: 155cm111
50. Insel TR, Cuthbert BN (2009) Endophenotypes: bridging genomic complexity and disorder heterogeneity. Biol Psychiatry 66: 988-989
51. Jerlhag E, Egecioglu E, Dickson SL, Andersson M, Svensson L, Engel JA (2006) Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: implications for its involvement in brain reward. Addict Biol 11: 45-54
52. Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, Datta R, Perrissoud D, Dickson SL, Engel JA (2009) Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A 106: 11318-11323
53. John U, Rumpf HJ, Bischof G, Hapke U, Hanke M, Meyer C (2013) Excess mortality of alcohol-dependent individuals after 14 years and mortality predictors based on treatment participation and severity of alcohol dependence. Alcohol Clin Exp Res 37: 156-163
54. Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R, Kim MM, Shanahan E, Gass CE, Rowe CJ, Garbutt JC (2014) Pharmacotherapy for adults with alcohol use disorders in outpatient settings a systematic review and meta-analysis. Jama-J Am Med Assoc 311: 1889-1900
55. Joos L, Goudriaan AE, Schmaal L, Fransen E, van den Brink W, Sabbe BG, Dom G (2013) Effect of modafinil on impulsivity and relapse in alcohol dependent patients: a randomized, placebo-controlled trial. Eur Neuropsychopharmacol 23: 948-955
56. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US food and drug administration in support of new drug applications. J Clin Psychiatry 72: 464-472
57. Knutson B, Gibbs SE (2007) Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology 191: 813-822
58. Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53
59. Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R, Rio DE, Huestis M, Anizan S, Concheiro M, Sinha R, Heilig M (2014) The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology
60. Landgren S, Simms JA, Hyytia P, Engel JA, Bartlett SE, Jerlhag E (2012) Ghrelin receptor (GHS-R1A) antagonism suppresses both operant alcohol self-administration and high alcohol consumption in rats. Addict Biol 17: 86-94
61. Litten RZ, Egli M, Heilig M, Cui C, Fertig JB, Ryan ML, Falk DE, Moss H, Huebner R, Noronha A (2012) Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol 17: 513-527
62. Mann K, Bladstrom A, Torup L, Gual A, van den Brink W (2013) Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol Psychiatry 73: 706-713
63. Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR (2009) Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend 99: 345-349
64. Mark TL, Kranzler HR, Song X (2003) Understanding US addiction physicians’ low rate of naltrexone prescription. Drug Alcohol Depend 71: 219-228
65. Martinez D, Gil R, Slifstein M, Hwang DR, Huang Y, Perez A, Kegeles L, Talbot P, Evans S, Krystal J, Laruelle M, Abi-Dargham A (2005) Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 58: 779-786
66. Meinhardt MW, Hansson AC, Perreau-Lenz S, Bauder-Wenz C, Stahlin O, Heilig M, Harper C, Drescher KU, Spanagel R, Sommer WH (2013) Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J Neurosci 33: 2794-2806
67. Meinhardt MW, Sommer WH (2015) Postdependent state in rats as a model for medication development in alcoholism. Addict Biol 20: 1-21
68. Miller G (2010) Is pharma running out of brainy ideas? Science 329: 502-504
69. Molander A, Vengeliene V, Heilig M, Wurst W, Deussing JM, Spanagel R (2012) Brain-specific inactivation of the Crhr1 gene inhibits post-dependent and stress-induced alcohol intake, but does not affect relapse-like drinking. Neuropsychopharmacology 37: 1047-1056
70. Muller-Oehring EM, Jung YC, Pfefferbaum A, Sullivan EV, Schulte T (2014) The resting brain of alcoholics. Cereb Cortex
71. Munafo MR, Brown SM, Hariri AR (2008) Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry 63: 852-857
72. Nutt DJ, King LA, Phillips LD, Independent Scientific Committee on D (2010) Drug harms in the UK: a multicriteria decision analysis. Lancet 376: 1558-1565
73. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887
74. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O’Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552
75. Piazza PV, Deroche-Gamonet V (2013) A multistep general theory of transition to addiction. Psychopharmacology 229: 387-413
76. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2011) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817
77. Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Vogl AM, Dedic N, Schumacher M, von Wolff G, Avrabos C, Touma C, Engblom D, Schutz G, Nave KA, Eder M, Wotjak CT, Sillaber I, Holsboer F, Wurst W, Deussing JM (2011) Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333: 1903-1907
78. Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos CT (2003) The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 98: 1209-1228
79. Rossetti ZL, Carboni S (1995) Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur J Pharmacol 283: 177-183
80. Schizophrenia Working Group of the Psychiatric Genomics C (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511: 421-427
81. Schmaal L, Goudriaan AE, Joos L, Kruse AM, Dom G, van den Brink W, Veltman DJ (2013) Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biol Psychiatry 73: 789-795
82. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S, Plisson C, Miller SR, Huiban M, Beaver JD, Gunn RN, Laruelle M, Rabiner EA (2012) Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32: 127-136
83. Sillaber I, Rammes G, Zimmermann S, Mahal B, Zieglgansberger W, Wurst W, Holsboer F, Spanagel R (2002) Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science 296: 931-933
84. Spagnolo PA, Ramchandani VA, Schwandt ML, Zhang L, Blaine SK, Usala JM, Diamond KA, Phillips MJ, George DT, Momenan R, Heilig M (2014) Effects of naltrexone on neural and subjective response to alcohol in treatment-seeking alcohol-dependent patients. Alcohol Clin Exp Res 38: 3024-3032
85. Spanagel R (2009) Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 89: 649-705
86. Spanagel R (2010) Are metabotropic glutamate receptors promising targets for the treatment of alcoholism? Biol Psychiatry 67: 798-799
87. Spanagel R, Kiefer F (2008) Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol Sci 29: 109-115
88. Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC, Lascorz J, Depner M, Holzberg D, Soyka M, Schreiber S, Matsuda F, Lathrop M, Schumann G, Albrecht U (2005) The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 11: 35-42
89. Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F (2014) Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology 39: 783-791
90. Srinivasan R, Cunningham C, Chen A, Vigneron D, Hurd R, Nelson S, Pelletier D (2006) TE-averaged two-dimensional proton spectroscopic imaging of glutamate at 3 T. Neuroimage 30: 1171-1178
91. Tanda G, Di Chiara G (1998) A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci 10: 1179-1187
92. Trantham-Davidson H, Burnett EJ, Gass JT, Lopez MF, Mulholland PJ, Centanni SW, Floresco SB, Chandler LJ (2014) Chronic alcohol disrupts dopamine receptor activity and the cognitive function of the medial prefrontal cortex. J Neurosci 34: 3706-3718
93. Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L, Adams LJ, Vengeliene V, Spanagel R, Zhang Y, Shen J, George DT, Hommer D, Heilig M (2010) Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 67: 1069-1077
94. Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, Sakr E, Castillo F, Moadel T, O’Malley SS, Krystal JH, Abi-Dargham A (2010) Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [(11)C] raclopride. Biol Psychiatry 68: 689-696
95. Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9: 557-569
96. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880
97. Weiss F, Lorang MT, Bloom FE, Koob GF (1993) Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 267: 250-258
98. Westman J, Wahlbeck K, Laursen TM, Gissler M, Nordentoft M, Hallgren J, Arffman M, Osby U (2014) Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland and Sweden. Acta Psychiatr Scand
99. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382: 1575-1586
100. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S, Seeman P, Wilson AA, Kapur S (2008) First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33: 279-289
101. Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94: 469-492
102. Zhou Z, Karlsson C, Liang T, Xiong W, Kimura M, Tapocik JD, Yuan Q, Barbier E, Feng A, Flanigan M, Augier E, Enoch MA, Hodgkinson CA, Shen PH, Lovinger DM, Edenberg HJ, Heilig M, Goldman D (2013) Loss of metabotropic glutamate receptor 2 escalates alcohol consumption. Proc Natl Acad Sci U S A 110: 16963-16968
103. Zorrilla EP, Heilig M, de Wit H, Shaham Y (2013) Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128: 175-186